Enanta Pharmaceuticals, Inc. (ENTA) financial statements and ratios from SEC XBRL: revenue $65.32M (TTM), net margin -125.4%, revenue growth -21.6% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $65.32M |
| Net Margin | -125.4% |
| Revenue Growth (YoY) | -21.6% |
| EPS Growth (YoY) | -21.2% |
| FCF Growth (YoY) | 19.7% |
| Price / Book | 3.86 |
| Price / Sales | 5.80 |
| FCF Yield | -20.2% |
| Altman Z-Score | -1.05 (distress) |
| Sector P/E (Healthcare) | 21.7 |
ENTA overview · ENTA earnings · ENTA KPIs · ENTA investor relations · ENTA ownership · ENTA peers · ENTA filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.